Recommendations of the National Heart, Lung, and Blood Institute working group on cerebrovascular biology and disease
about
Drugs acting on SUR1 to treat CNS ischemia and traumaSecondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation.Intraluminal thread model of focal stroke in the non-human primate.Estrogen-receptor-mediated protection of cerebral endothelial cell viability and mitochondrial function after ischemic insult in vitroChloride channel blocker 4,4-diisothiocyanatostilbene-2,2'-disulfonic acid inhibits nitric oxide-induced apoptosis in cultured rat hippocampal neurons.Pharmaco-proteomics opportunities for individualizing neurovascular treatment.Proliferation in the Alzheimer hippocampus is due to microglia, not astroglia, and occurs at sites of amyloid deposition.Application of proteomics to cerebrovascular disease.Effects of minocycline on learning and memory of mice following ischemic-hypoxic cerebral injuriesVascular actions of estrogens: functional implications.Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapiesVascular neural network: the importance of vein drainage in stroke.Antioxidant approaches for the treatment of Alzheimer's disease.Developmental origins of cerebrovascular disease I: prenatal cerebrovascular development--classic findings in the context of advances in genetic and fetal surveillance evaluations.Genomics and proteomics are changing discovery, development and clinical use of dementia drugs.Androgens and the cerebrovasculature: modulation of vascular function during normal and pathophysiological conditions.Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment.
P2860
Q24655850-3C4B4694-6AC0-4517-83AF-D79437E56A69Q28221595-2FDB5302-CCE3-4D50-AC54-82349F50A5B1Q33276827-C0133688-8684-4DEB-81FD-A168D0DB1350Q33305426-A40B19F1-FAF3-41AE-BF58-E8F60518F69EQ33699129-1D253C7C-5B74-41F2-918C-5CDD451DDA23Q33936411-4741CEDE-188A-440A-AE93-BB4057C3FD98Q34128934-78F3F711-589B-49A6-B311-DE3A3622380CQ34146055-C05221DD-2997-41A1-A1B0-31E549369183Q34312457-7308E16A-4818-4D31-8699-93256CF92ABBQ35160728-B18B2D50-8709-44CE-B9C0-DEC5708FC669Q37088243-7356DB03-E7C3-49B6-A1E8-AED113C87074Q37308961-83CF75FA-090F-4C87-B262-B6B44B69C4A6Q37701135-7551A044-8CCC-40AF-AD44-DE83910CCD4AQ37768449-8112C551-AA4F-4FD5-AAD5-C6D0D84EBDE7Q37969733-9030C562-4EFF-4302-B730-AA5732CF5DC0Q38088754-A9CC666A-BDF2-43B9-8700-D9BA3BF4D29FQ38100664-7EDD6EED-7A96-4874-8D4A-CEEA18448219Q42446674-6355644A-81BB-4C72-8BB4-0C51B5F88C55
P2860
Recommendations of the National Heart, Lung, and Blood Institute working group on cerebrovascular biology and disease
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Recommendations of the Nationa ...... rovascular biology and disease
@ast
Recommendations of the Nationa ...... rovascular biology and disease
@en
type
label
Recommendations of the Nationa ...... rovascular biology and disease
@ast
Recommendations of the Nationa ...... rovascular biology and disease
@en
prefLabel
Recommendations of the Nationa ...... rovascular biology and disease
@ast
Recommendations of the Nationa ...... rovascular biology and disease
@en
P2093
P2860
P1433
P1476
Recommendations of the Nationa ...... rovascular biology and disease
@en
P2093
David R Harder
Donald D Heistad
J Marc Simard
Michael A Moskowitz
Michael A Sloan
Paul A Velletri
Richard J Traystman
Stephen S Goldman
Zvonimir S Katusic
P2860
P304
P356
10.1161/01.STR.0000221297.57305.8A
P407
P577
2006-04-20T00:00:00Z